Scotiabank Issues Pessimistic Forecast for Albemarle (NYSE:ALB) Stock Price

Albemarle (NYSE:ALB - Free Report) had its price target decreased by Scotiabank from $75.00 to $65.00 in a research report released on Tuesday,Benzinga reports. Scotiabank currently has a sector perform rating on the specialty chemicals company's stock. Scotiabank also issued estimates for Albemarle's Q2 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.71) EPS and FY2026 earnings at $1.50 EPS.

Other research analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Albemarle from $109.00 to $105.00 in a report on Wednesday, February 12th. TD Securities decreased their target price on Albemarle from $115.00 to $65.00 and set a "hold" rating on the stock in a research note on Thursday, May 1st. Citigroup dropped their price target on Albemarle from $85.00 to $64.00 and set a "neutral" rating for the company in a research note on Tuesday, April 15th. KeyCorp dropped their target price on shares of Albemarle from $102.00 to $95.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Finally, StockNews.com upgraded shares of Albemarle to a "sell" rating in a report on Monday, May 5th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $92.43.

Albemarle Stock Performance

Shares of ALB stock traded up $0.49 during mid-day trading on Tuesday, reaching $57.93. 2,162,897 shares of the company's stock traded hands, compared to its average volume of 2,763,102. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.19 and a current ratio of 1.95. The firm has a market capitalization of $6.82 billion, a PE ratio of -5.17 and a beta of 1.71. Albemarle has a 12 month low of $49.43 and a 12 month high of $137.50. The firm has a 50 day moving average price of $64.62 and a two-hundred day moving average price of $82.97.

Albemarle (NYSE:ALB - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The specialty chemicals company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.44. Albemarle had a negative return on equity of 1.72% and a negative net margin of 21.93%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.26 earnings per share. Albemarle's revenue for the quarter was down 20.9% on a year-over-year basis. On average, research analysts forecast that Albemarle will post -0.04 EPS for the current year.

Albemarle Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Friday, June 13th will be given a dividend of $0.405 per share. This represents a $1.62 annualized dividend and a yield of 2.80%. The ex-dividend date is Friday, June 13th. Albemarle's dividend payout ratio is currently -14.57%.

Institutional Investors Weigh In On Albemarle

A number of large investors have recently modified their holdings of ALB. Assetmark Inc. grew its position in Albemarle by 340.6% during the 4th quarter. Assetmark Inc. now owns 304 shares of the specialty chemicals company's stock worth $26,000 after purchasing an additional 235 shares during the last quarter. Trust Co. of Vermont increased its position in shares of Albemarle by 606.5% in the 4th quarter. Trust Co. of Vermont now owns 325 shares of the specialty chemicals company's stock valued at $28,000 after acquiring an additional 279 shares during the period. SJS Investment Consulting Inc. purchased a new position in Albemarle in the 1st quarter worth $32,000. First Community Trust NA grew its stake in Albemarle by 55.0% during the 4th quarter. First Community Trust NA now owns 400 shares of the specialty chemicals company's stock valued at $34,000 after purchasing an additional 142 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Albemarle in the fourth quarter valued at about $34,000. Hedge funds and other institutional investors own 92.87% of the company's stock.

About Albemarle

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Energy Storage, Specialties and Ketjen. The Energy Storage segment offers lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride; technical services for the handling and use of reactive lithium products; and lithium-containing by-products recycling services.